Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Common Equity: 2014-2024

Historic Common Equity for Viking Therapeutics (VKTX) over the last 11 years, with Dec 2024 value amounting to $880.3 million.

  • Viking Therapeutics' Common Equity fell 21.77% to $713.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $713.0 million, marking a year-over-year decrease of 21.77%. This contributed to the annual value of $880.3 million for FY2024, which is 152.65% up from last year.
  • As of FY2024, Viking Therapeutics' Common Equity stood at $880.3 million, which was up 152.65% from $348.4 million recorded in FY2023.
  • Viking Therapeutics' Common Equity's 5-year high stood at $880.3 million during FY2024, with a 5-year trough of $145.3 million in FY2022.
  • Its 3-year average for Common Equity is $458.0 million, with a median of $348.4 million in 2023.
  • Its Common Equity has fluctuated over the past 5 years, first decreased by 28.02% in 2022, then surged by 152.65% in 2024.
  • Yearly analysis of 5 years shows Viking Therapeutics' Common Equity stood at $244.3 million in 2020, then declined by 17.38% to $201.9 million in 2021, then decreased by 28.02% to $145.3 million in 2022, then surged by 139.76% to $348.4 million in 2023, then surged by 152.65% to $880.3 million in 2024.